These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22789835)

  • 1. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
    Bournia VK; Evangelou K; Sfikakis PP
    Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
    Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
    Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.
    Sabnani I; Zucker MJ; Rosenstein ED; Baran DA; Arroyo LH; Tsang P; Zubair M; Rivera V
    Rheumatology (Oxford); 2009 Jan; 48(1):49-52. PubMed ID: 18815156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is imatinib mesylate a promising drug in systemic sclerosis?
    van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
    Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
    Beyer C; Distler JH; Distler O
    Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
    Bibi Y; Gottlieb AB
    J Am Acad Dermatol; 2008 Oct; 59(4):654-8. PubMed ID: 18571768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib and the treatment of fibrosis: recent trials and tribulations.
    Gordon J; Spiera R
    Curr Rheumatol Rep; 2011 Feb; 13(1):51-8. PubMed ID: 21086081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
    Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
    Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary toxicities of tyrosine kinase inhibitors.
    Peerzada MM; Spiro TP; Daw HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
    Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
    N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
    Sánchez-Ortega I; Servitje O; Arnan M; Ortí G; Peralta T; Manresa F; Duarte RF
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):318-23. PubMed ID: 22068151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.
    Merx K; Fabarius A; Erben P; Griesshammer M; Reiter A; Hofmann WK; Hehlmann R; Hochhaus A; Lengfelder E
    Ann Hematol; 2013 Jul; 92(7):907-15. PubMed ID: 23525684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
    Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
    Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.
    Tamaki Z; Asano Y; Hatano M; Yao A; Kawashima T; Tomita M; Kinugawa K; Nagai R; Sato S
    Mod Rheumatol; 2012 Feb; 22(1):94-9. PubMed ID: 21633912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.